Literature DB >> 17548492

Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.

Eric G Solon1, James A Dowell, Jonghui Lee, S Peter King, Bharat D Damle.   

Abstract

Penetration of dalbavancin into noninfected bone and joint tissues was assessed after an intravenous dose of 20 mg/kg (of body weight) [(14)C]dalbavancin given to rabbits. Drug-derived radioactivity, determined over 14 days by either liquid scintillation counting or autoradiography, remained above the MIC for common gram-positive pathogens that cause bone and joint infections.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17548492      PMCID： PMC1932505          DOI： 10.1128/AAC.00020-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Diekema; M A Pfaller; F J Schmitz; J Smayevsky; J Bell; R N Jones; M Beach
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

2.  Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

Authors:  Ronald N Jones; Matthew G Stilwell; Helio S Sader; Thomas R Fritsche; Beth P Goldstein
Journal:  Diagn Microbiol Infect Dis       Date:  2006-01-19       Impact factor: 2.803

3.  Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.

Authors:  Gengrong Lin; Kim Credito; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide.

Authors:  Mary Buckwalter; James A Dowell
Journal:  J Clin Pharmacol       Date:  2005-11       Impact factor: 3.126

5.  Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.

Authors:  Luis E Jauregui; Simon Babazadeh; Elyse Seltzer; Lisa Goldberg; Dainis Krievins; Mark Frederick; David Krause; Igors Satilovs; Zilvinas Endzinas; Jeffrey Breaux; William O'Riordan
Journal:  Clin Infect Dis       Date:  2005-10-06       Impact factor: 9.079

Review 6.  Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.

Authors:  Mary Beth Dorr; Daniela Jabes; Marco Cavaleri; James Dowell; Giorgio Mosconi; Adriano Malabarba; Richard J White; Timothy J Henkel
Journal:  J Antimicrob Chemother       Date:  2005-03       Impact factor: 5.790

7.  Efficacy of teicoplanin and autoradiographic diffusion pattern of [14C]teicoplanin in experimental Staphylococcus aureus infection of joint prostheses.

Authors:  A Saleh Mghir; A C Crémieux; R Bleton; F Ismael; M Manteau; S Dautrey; L Massias; L Garry; N Sales; B Mazière; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

8.  Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.

Authors:  Jennifer M Streit; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-02       Impact factor: 2.803

Review 9.  Antibiotic treatment of gram-positive bone and joint infections.

Authors:  Elizabeth S R Darley; Alasdair P MacGowan
Journal:  J Antimicrob Chemother       Date:  2004-04-29       Impact factor: 5.790
  9 in total
  10 in total

1.  Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.

Authors:  Michael W Dunne; Sailaja Puttagunta; Craig R Sprenger; Chris Rubino; Scott Van Wart; James Baldassarre
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.

Authors:  Kyle C Molina; Matthew A Miller; Scott W Mueller; Edward T Van Matre; Martin Krsak; Tyree H Kiser
Journal:  Clin Pharmacokinet       Date:  2021-12-21       Impact factor: 5.577

3.  Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.

Authors:  Dario Lehoux; Valerie Ostiguy; Cordelia Cadieux; Mireille Malouin; Odette Belanger; Adel Rafai Far; Thomas R Parr
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

4.  Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats.

Authors:  Wen Lin; Jimmy Flarakos; Yancy Du; Wenyu Hu; Handan He; James Mangold; S Ken Tanaka; Stephen Villano
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.

Authors:  Thamer A Almangour; Valerie Fletcher; Mohammed Alessa; Abdullah A Alhifany; Deanne Tabb
Journal:  Am J Case Rep       Date:  2017-12-09

6.  Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study.

Authors:  Thamer A Almangour; Gregory K Perry; Abdullah A Alhifany
Journal:  Saudi Pharm J       Date:  2020-02-17       Impact factor: 4.330

Review 7.  Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.

Authors:  Oriana Simonetti; Giulio Rizzetto; Elisa Molinelli; Oscar Cirioni; Annamaria Offidani
Journal:  Ther Clin Risk Manag       Date:  2021-03-22       Impact factor: 2.423

Review 8.  Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.

Authors:  Luis Buzón-Martín; I Zollner-Schwetz; Selma Tobudic; Emilia Cercenado; Jaime Lora-Tamayo
Journal:  Antibiotics (Basel)       Date:  2021-05-31

9.  A young patient with fever after heart transplantation.

Authors:  R Vates; S J Rodríguez; M E Martínez; J A Martínez
Journal:  Rev Esp Quimioter       Date:  2018-09-14       Impact factor: 1.553

10.  Orthopaedic Implant-Associated Staphylococcal Infections: A Critical Reappraisal of Unmet Clinical Needs Associated with the Implementation of the Best Antibiotic Choice.

Authors:  Milo Gatti; Simona Barnini; Fabio Guarracino; Eva Maria Parisio; Michele Spinicci; Bruno Viaggi; Sara D'Arienzo; Silvia Forni; Angelo Galano; Fabrizio Gemmi
Journal:  Antibiotics (Basel)       Date:  2022-03-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.